In MAPS’s trials, scientists dose PTSD individuals with copyright just before guiding them through a psychotherapy session—they’ve uncovered evidence the drug will help clients faucet into the trauma at the Main in their ailment without needing to relive it in the exact same visceral, terrifying way they would when they have been sober. MAPS